Loading...
XCNQ
ENBI
Market cap978kUSD
, Last price  
CAD
Name

Entheon Biomedical Corp

Chart & Performance

D1W1MN
XCNQ:ENBI chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
37.34%
Rev. gr., 5y
%
Revenues
0k
00000021,670189,677250,32300
Net income
-324k
L+1.89%
-8,862-1,859-145,000-158,000-667,000-4,378,032-8,887,000-8,521,000-300,000-318,000-324,012
CFO
-315k
L-11.52%
-8,784-2,033-67,492-221,312-102,317-2,837,522-5,615,218-1,954,608-359,929-355,639-314,659

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Entheon Biomedical Corp. functions as a biotechnology firm focused on the research and development of novel pharmaceuticals. The company is actively involved in pioneering and introducing to market psychedelic therapeutic products, specifically those derived from N,N-dimethyltryptamine (DMT), with the aim of combating addiction and various substance use disorders. Its services are provided to medical doctors, healthcare facilities, and accredited psychiatrists across Canada, the United States, and the European Union. Entheon Biomedical Corp.'s primary operations are based in Vancouver, Canada.
IPO date
May 03, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑112024‑112023‑112022‑112021‑112020‑112020‑032019‑112019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT